Angiogenesis and Anti-angiogenic Therapy in Myelofibrosis with Myeloid Metaplasia

References

• Hanahan, D. and Weinberg, R.A. (2000) "The hallmarks of cancer", Cell, 100, 57–70.
   Google Scholar
• Kerbel, R.S. (2000) "Tumor angiogenesis: past, present and the near future", Carcinogenesis, 21, 505–515.
   Google Scholar
• Fox, S.B. (1997) "Tumour angiogenesis and prognosis", Histo-pathology, 30, 294–301.
   Google Scholar
• Weidner, N. (1993) "Tumor angiogenesis — review of current applications in tumor prognostication", Semin. Diagn. Pathol., 10, 302–313.
   Web of Science ®Google Scholar
• Rajkumar, S.V., Mesa, R.A. and Tefferi, A. (2002) "A review of angiogenesis and anti-angiogenic therapy in hematologic malig-nancies", Journal of Hematotherapy & Stem Cell Research, 11, 33 — 47.
   PubMedGoogle Scholar
• Rajkumar, S.V., Leong, T., Roche, P.C., Fonseca, R., Dispenzieri, A., Lacy, M.Q., et al. (2000) "Prognostic value of bone marrow angiogenesis in multiple myeloma", Clin. Cancer Res., 6, 3111 — 3116.
   Web of Science ®Google Scholar
• Follcman, J. and Shing, Y. (1992) "Angiogenesis", J. Biol. Chem., 267, 10931–10934.
   Web of Science ®Google Scholar
• Risau, W., Sariola, H., Zerwes, H.G., Sasse, J., Ekblom, P., Kemler, R., et al. (1988) "Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies", Development, 102, 471 —478.
   Google Scholar
• Shi, Q., Rafii, S., Wu, M.H., Wijelath, E.S., Yu, C., Ishida, A., et al. (1998) "Evidence for circulating bone marrow-derived en-dothelial cells", Blood, 92, 362— 367.
   Google Scholar
• Dvorak, H.F. (2002) "Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy", J. Clin. Oncol., 20, 4368–4380.
   Web of Science ®Google Scholar
• Dvorak, H.F. (1986) "Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing", N. Engl. J. Med., 315, 1650 — 1659.
   Google Scholar
• Koch, A.E. (1998) "Review: angiogenesis: implications for rheumatoid arthritis", Arthritis Rheum., 41, 951–962.
   PubMed Web of Science ®Google Scholar
• Koch, A.E., Polverini, P.J. and Leibovich, S.J. (1986) "Induction of neovascularization by activated human monocytes", J. Leukoc. Biol., 39, 233–238.
   PubMed Web of Science ®Google Scholar
• Follcman, J. (1996) "Fighting cancer by attacking its blood supply", Sci. Am., 275, 150–154.
   Google Scholar
• Follcman, J. (1995) "Angiogenesis in cancer, vascular, rheumatoid and other disease", Nat. Med., 1, 27 — 31.
   Web of Science ®Google Scholar
• Hanahan, D. and Folkman, J. (1996) "Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis", Cell, 86, 353 — 364.
   Google Scholar
• Risau, W. (1997) "Mechanisms of angiogenesis", Nature, 386, 671 —674.
   Web of Science ®Google Scholar
• Bergers, G. and Benjamin, L.E. (2003) "Tumorigenesis and the angiogenic switch", Nat. Rev. Cancer, 3, 401–410.
   PubMed Web of Science ®Google Scholar
• Morikawa, S., Baluk, P., Kaidoh, T., Haskell, A., Jain, R.K. and McDonald, D.M. (2002) "Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors", Am. J. Pathol., 160, 985–1000.
   Web of Science ®Google Scholar
• Takahashi, Y., Bucana, C.D., Liu, W., Yoneda, J., Kitadai, Y., Cleary, K.R., et al. (1996) "Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells", J. Natl. Cancer Inst., 88, 1146–1151.
   Google Scholar
• List, A.F. (2001) "Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies", Oncologist, 6\(Suppl 5), 24–31.
   PubMed Web of Science ®Google Scholar
• Ferrara, N. and Alitalo, K. (1999) "Clinical applications of angiogenic growth factors and their inhibitors", Nat. Med., 5, 1359–1364.
   Web of Science ®Google Scholar
• Cohen, T., Nahari, D., Cerem, L.W., Neufeld, G. and Levi, B.Z. (1996) "Interleulcin 6 induces the expression of vascular endothelial growth factor", J. Biol. Chem., 271, 736–741.
   Web of Science ®Google Scholar
• Brogi, E., Wu, T., Namilci, A. and Isner, J.M. (1994) "Indirect angiogenic cytolcines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only", Circulation, 90, 649–652.
   Google Scholar
• Veikkola, T. and Alitalo, K. (1999) "VEGFs, receptors and angiogenesis", Semin. Cancer Biol., 9, 211 — 220.
   PubMed Web of Science ®Google Scholar
• Veikkola, T., Karkkainen, M., Claesson-Welsh, L. and Alitalo, K. (2000) "Regulation of angiogenesis via vascular endothelial growth factor receptors", Cancer Res., 60, 203–212.
   PubMed Web of Science ®Google Scholar
• Heil, M., Clauss, M., Suzuki, K., Buschmann, I.R., Willuweit, A., Fischer, S., et al. (2000) "Vascular endothelial growth factor (VEGF) stimulates monocyte migration through endothelial monolayers via increased integrin expression", Eur. J. Cell. Biol., 79, 850–857.
   Web of Science ®Google Scholar
• Gospodarowicz, D., Ferrara, N., Schweigerer, L. and Neufeld, G. (1987) "Structural characterization and biological functions of fibroblast growth factor", Endocr. Rev., 8, 95–114.
   Google Scholar
• Asahara, T., Bauters, C., Zheng, L.P., Takeshita, S., Bunting, S., Ferrara, N., et al. (1995) "Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo", Circulation, 92, 11365–11371.
   Google Scholar
• Tsigkos, S., Koutsilieris, M. and Papapetropoulos, A. (2003) "Angiopoietins in angiogenesis and beyond", Expert Opin. Investig. Drugs, 12, 933–941.
   Web of Science ®Google Scholar
• Peters, K.G. (1998) "Vascular endothelial growth factor and the angiopoietins: working together to build a better blood vessel", Circ. Res., 83, 342— 343.
   Google Scholar
• Hynes, R.O. (1992) "Integrins: versatility, modulation, and signaling in cell adhesion", Cell, 69, 11— 25.
   Google Scholar
• Li, C.Y., Shan, S., Huang, Q., Braun, R.D., Lanzen, J., Hu, K., et al. (2000) "Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models", J. Natl. Cancer Inst., 92, 143–147.
   Google Scholar
• Dawson, D.W., Pearce, S.F., Zhong, R., Silverstein, R.L., Frazier, W.A. and Bouck, N.P. (1997) "CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells", J. Cell. Biol., 138, 707 —717.
   PubMed Web of Science ®Google Scholar
• Good, DJ., Polverini, P.J., Rastinejad, F., Le Beau, MM., Lemons, R.S., Frazier, W.A. and Bouck, N.P. (1990) "A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombos-pondin", Proc. Nat! Acad. Sci. USA, 87, 6624 — 6628.
   PubMed Web of Science ®Google Scholar
• Jimenez, B., Volpert, 0.V., Crawford, SE., Febbraio, M., Silverstein, R.L. and Bouck, N. (2000) "Signals leading to apoptosis-dependent inhibition of neovascularization by throm-bospondin-1", Nat. Med., 6, 41 — 48.
   Google Scholar
• Guo, N., Krutzsch, H.C., Inman, J.K. and Roberts, D.D. (1997) "Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells", Cancer Res., 57, 1735–1742.
   Google Scholar
• Claesson-Welsh, L., Welsh, M., Ito, N., Anand-Apte, B., Soker, S., Zetter, B., et al. "Angiostatin induces endothelial cell apoptosis and activation of focal adhesion lcinase independently of the integrin-binding motif RGD", Proc. Nat! Acad. Sci. USA, 95, 5579— 5583.
   Google Scholar
• Kim, Y.M., Hwang, S., Pyun, B.J., Kim, T.Y., Lee, ST., Gho, Y.S., et al. (2002) "Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1", J. Biol. Chem., 277, 27872–27879.
   Web of Science ®Google Scholar
• Brooks, P.C., Silletti, S., von Schalscha, T.L., Friedlander, M. and Cheresh, D.A. (1998) "Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity", Cell, 92, 391 — 400.
   Google Scholar
• Bello, L., Lucini, V., Carrabba, G., Giussani, C., Machluf, M., Pluderi, M., et al. (2001) "Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2", Cancer Res., 61, 8730–8736.
   PubMed Web of Science ®Google Scholar
• John, A. and Tuszynslci, G. (2001) "The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis", PathoL OncoL Res., 7, 14–23.
   PubMedGoogle Scholar
• Burbridge, M.F., Coge, F., Galizzi, J.P., Boutin, J.A., West, D.C. and Tucker, G.C. (2002) "The role of the matrix metalloprotei-nases during in vitro vessel formation", Angiogenesis, 5, 215–226.
   Google Scholar
• Barleon, B., Reusch, P., Totzke, F., Herzog, C., Keck, C., Martiny-Baron, G., et al. (2001) "Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors", Angiogenesis, 4, 143–154.
   PubMedGoogle Scholar
• Reusch, P., Barleon, B., Weindel, K., Martiny-Baron, G., Godde, A., Siemeister, G., et al. (2001) "Identification of a soluble form of the angiopoietin receptor TIE-2 released from endothelial cells and present in human blood", Angiogenesis, 4, 123–131.
   PubMedGoogle Scholar
• Liotta, L.A. and Kohn, E.C. (2001) "The microenvironment of the tumour-host interface", Nature, 411, 375— 379.
   Google Scholar
• Laderoute, KR., Alarcon, R.M., Brody, M.D., Calaoagan, J.M., Chen, E.Y., Knapp, A.M., et al. (2000) "Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor", Clin. Cancer Res., 6, 2941 —2950.
   Web of Science ®Google Scholar
• Royds, JA., Dower, S.K., Qwarnstrom, E.E. and Lewis, C.E. (1998) "Response of tumour cells to hypoxia: role of p53 and NFkB", Mol. Pathol., 51, 55–61.
   Web of Science ®Google Scholar
• Mukhopadhyay, D., Tsiokas, L. and Sukhatme, V.P. (1995) "Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression", Cancer Res., 55, 6161–6165.
   PubMed Web of Science ®Google Scholar
• Dameron, KM., Volpert, 0.V., Tainsky, MA. and Bouck, N. (1994) "Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1", Science, 265, 1582— 1584.
   Google Scholar
• Bian, J. and Sun, Y. (1997) "Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metallo-proteinase 2) promoter", MoL Cell. Biol., 17, 6330–6338.
   Google Scholar
• Brantley, D.M., Cheng, N., Thompson, E.J., Lin, Q., Brekken, R.A., Thorpe, P.E., et al. (2003) "Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo", Oncogene, 21, 7011 — 7026.
   Google Scholar
• Sun, Y., Wenger, L., Rutter, J.L., Brinckerhoff, CE. and Cheung, H.S. (1999) "Human metalloproteinase-1 (collagenase-1) is a tumor suppressor protein p53 target gene", Ann. NY Acad. Sci., 878, 638–641.
   Google Scholar
• Pal, S., Datta, K. and Mukhopadhyay, D. (2001) "Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma", Cancer Res., 61, 6952–6957.
   PubMed Web of Science ®Google Scholar
• Ravi, R., Mookerjee, B., Bhujwalla, Z.M., Sutter, C.H., Artemov, D., Zeng, Q., et al. (2000) "Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 alpha", Genes Dev., 14, 34–44.
   PubMed Web of Science ®Google Scholar
• Subbaramaiah, K., Altorlci, N., Chung, W.J., Mestre, J.R., Sampat, A. and Dannenberg, A.J. (1999) "Inhibition of cycloox-ygenase-2 gene expression by p53", J. Biol. Chem., 274, 109 11 — 10915.
   Google Scholar
• Kerbel, R. and Follcman, J. (2002) "Clinical translation of angiogenesis inhibitors", Nat. Rev. Cancer, 2, 727–739.
   PubMed Web of Science ®Google Scholar
• Ngo, CV., Gee, M., Akhtar, N., Yu, D., Volpert, 0., Auerbach, R., et al. (2000) "An in vivo function for the transforming Myc protein: elicitation of the angiogenic phenotype", Cell Growth Differ., 11, 201–210.
   PubMedGoogle Scholar
• Arbiser, J.L., Petros, J., Klafter, R., Govindajaran, B., McLaugh-lin, ER., Brown, L.F., et al. (2002) "Reactive oxygen generated by No x 1 triggers the angiogenic switch", Proc. Nat! Acad. Sci. USA, 99, 715–720.
   PubMed Web of Science ®Google Scholar
• Kerbel, R.S., Viloria-Petit, A., Okada, F. and Rak, J. (1998) "Establishing a link between oncogenes and tumor angiogenesis", Mol. Med., 4, 286–295.
   Web of Science ®Google Scholar
• Sonobe, M.H., Bravo, R. and Armelin, M.S. (1991) "Imbalanced expression of cellular nuclear oncogenes caused by v-sis/PDGF-2", Oncogene, 6, 1531–1537.
   PubMed Web of Science ®Google Scholar
• Valentinis, B., Morrione, A., Taylor, S.J. and Baserga, R. (1997) "Insulin-like growth factor I receptor signaling in transformation by src oncogenes", MoL Cell Biol., 17, 3744— 3754.
   Web of Science ®Google Scholar
• Hilgenfeld, E., Padilla-Nash, H., McNeil, N., Knutsen, T., Montagna, C., Tchinda, J., et al. (2001) "Spectral karyotyping and fluorescence in situ hybridization detect novel chromosomal aberrations, a recurring involvement of chromosome 21 and amplification of the MYC oncogene in acute myeloid leukaemia M2", Br. J. HaematoL, 113, 305–317.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau, H., Gerson, F., Magrangeas, F., Minvielle, S., Harousseau, J.L. and Bataille, R. (2001) "Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors", Blood, 98, 3082— 3086.
   Web of Science ®Google Scholar
• Foss, H.D., Araujo, I., Demel, G., Klotzbach, H., Hummel, M. and Stein, H. (1997) "Expression of vascular endothelial growth factor in lymphomas and Castleman's disease", J. PathoL, 183, 44 — 50.
   PubMed Web of Science ®Google Scholar
• Dankbar, B., Padro, T., Leo, R., Feldmann, B., Kropff, M., Mesters, R.M., et al. (2000) "Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma", Blood, 95, 2630–2636.
   PubMed Web of Science ®Google Scholar
• Aguayo, A., Estey, E., Kantarjian, H., Mansouri, T., Gidel, C., Keating, M., et al. (1999) "Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia", Blood, 94, 3717 — 3721.
   Google Scholar
• Aguayo, A., Kantarjian, H., Manshouri, T., Gidel, C., Estey, E., Thomas, D., et al. (2000) "Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes", Blood, 96, 2240 — 2245.
   Google Scholar
• Winter, S.S., Sweatman, ii., Lawrence, MB., Rhoades, T.H., Hart, A.L. and Larson, R.S. (2001) "Enhanced T-lineage acute lymphoblastic leukaemia cell survival on bone marrow stroma requires involvement of LFA-1 and ICAM-1", Br. J. Haematol., 115, 862–871.
   Web of Science ®Google Scholar
• Stucici, A., Rivier, AS., Gilcic, M., Monai, N., Schapira, M. and Spertini, 0. (2001) "Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemina-tion", Blood, 97, 2121–2129.
   Google Scholar
• Damian°, JS., Hazlehurst, L.A. and Dalton, W.S. (2001) "Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation", Leukemia, 15, 1232–1239.
   PubMed Web of Science ®Google Scholar
• Watarai, M., Miwa, H., Shikami, M., Sugamura, K., Wakabaya-shi, M., Satoh, A., et al. (2002) "Expression of endothelial cell-associated molecules in AML cells", Leukemia, 16, 112–119.
   PubMed Web of Science ®Google Scholar
• Tai, Y.T., Podar, K., Gupta, D., Lin, B., Young, G., Akiyama, M., et al. (2002) "CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells", Blood, 99, 1419 — 1427.
   Google Scholar
• Gupta, D., Treon, S.P., Shima, Y., Hideshima, T., Podar, K., Tai, Y.T., et al. (2001) "Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications", Leukemia, 15, 1950 — 1961.
   PubMed Web of Science ®Google Scholar
• Vacca, A., Ribatti, D., Roncali, L., Ranieri, G., Serio, G., Silvestris, F., et al. (1994) "Bone marrow angiogenesis and progression in multiple myeloma", Br. J. Haematol., 87, 503–508.
   Web of Science ®Google Scholar
• Bostwick, D.G., Wheeler, TM., Blute, M., Barrett, D.M., MacLennan, G.T., Sebo, Ti., et al. (1996) "Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies", Urology, 48, 47–57.
   Google Scholar
• Deyoung, B., Swanson, P.E., Sirgi, K.E., Fitzgibbon, J.F. and Wick, M.R. (1993) "Cd-31 immunoreactivity is specific for endothelial differentiation in human neoplasms", Lab. Invest., 68, AS.
   Google Scholar
• Mangi, M.H. and Newland, A.C. (2000) "Angiogenesis and angiogenic mediators in haematological malignancies", Br. J. Haematol., 111, 43–51.
   Web of Science ®Google Scholar
• Vanderijn, M. and Rouse, R.V. (1994) "Cd34 - a review", Applied Immunohistochemistry, 2, 71–80.
   Google Scholar
• Mesa, R.A., Hanson, CA., Rajkumar, S.V., Schroeder, G. and Tefferi, A. (2000) "Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia", Blood, 96, 3374–3380.
   Google Scholar
• Weidner, N., Semple, J.P., Welch, W.R. and Follcman, J. (1991) "Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma", N. Engl. J. Med., 324, 1–8.
   Google Scholar
• De Raeve, H., Van Marck, E., Van Camp, B. and Vanderkerken, K. (2004) "Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies", HistoL HistopathoL, 19, 935— 950.
   Google Scholar
• Weber, W.A., Haubner, R., Vabuliene, E., Kuhnast, B., Wester, H.J. and Schwaiger, M. (2001) "Tumor angiogenesis targeting using imaging agents", Q. J. Nucl. Med., 45, 179 — 182.
   Web of Science ®Google Scholar
• Schirner, M., Menrad, A., Stephens, A., Frenzel, T., Hauff, P. and Licha, K. (2004) "Molecular imaging of tumor angiogenesis", Ann. NY Acad. Sci., 1014, 67–75.
   Google Scholar
• Brunner, G., Nguyen, H., Gabrilove, J., Rifkin, D.B. and Wilson, E.L. (1993) "Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells", Blood, 81, 631–638.
   Google Scholar
• Bikfalvi, A. and Han, Z.C. (1994) "Angiogenic factors are hematopoietic growth factors and vice versa", Leukemia, 8, 523 — 529.
   Google Scholar
• Follcman, J., Browder, T. and Palmblad, J. (2001) "Angiogenesis research: guidelines for translation to clinical application", Thromb. Haemost., 86, 23–33.
   Google Scholar
• Rabascio, C., Muratori, E., Mancuso, P., Calleri, A., Raia, V., Foutz, T., et al. (2004) "Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells", Cancer Res., 64, 4373 — 4377.
   Web of Science ®Google Scholar
• Di Raimondo, F., Azzaro, M.P., Palumbo, G., Bagnato, S., Giustolisi, G., Floridia, P., et al. (2000) "Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood", Haematologica, 85, 800–805.
   Google Scholar
• Vuorela, P., Helske, S., Hornig, C., Alitalo, K., Weich, H. and Halmesmalci, E. (2000) "Amniotic fluid — soluble vascular endothe-lial growth factor receptor-1 in preeclampsia", Obstet. GynecoL, 95, 353–357.
   Google Scholar
• Ziegler, B.L., Valtieri, M., Porada, G.A., De Maria, R., Muller, R., Masella, B., et al. (1999) "KDR receptor: a key marker defining hematopoietic stem cells", Science, 285, 1553— 1558.
   Google Scholar
• Tefferi, A. (2000) "Myelofibrosis with myeloid metaplasia", N. Engl. J. Med., 342, 1255 — 1265.
   Google Scholar
• Reilly, J.T. (1997) "Idiopathic myelofibrosis: pathogenesis, natural history and management. [Review] [99 refs]", Blood Rev.,11, 233 — 242.
   Web of Science ®Google Scholar
• Jacobson, R.J., Salo, A. and Fialkow, P.J. (1978) "Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis", Blood, 51, 189 — 194.
   Google Scholar
• Dalley, A., Smith, J.M., Reilly, J.T. and Neil, S.M. (1996) "Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation", Br. J. Haematol., 93, 856–862.
   Web of Science ®Google Scholar
• Le Bousse-Kerdiles, MC., Chevillard, S., Charpentier, A., Romquin, N., Clay, D., Smadja-Joffe, F., et al. (1996) "Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34 + hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia", Blood, 88, 4534–4546.
   PubMed Web of Science ®Google Scholar
• Martyre, MC., Le Bousse-Kerdiles, MC., Romquin, N., Chevil-lard, S., Praloran, V., Demory, J.L. and Dupriez, B. (1997) "Elevated levels of basic fibroblast growth factor in megakaryo-cytes and platelets from patients with idiopathic myelofibrosis", Br. J. Haematol., 97, 441–448.
   PubMed Web of Science ®Google Scholar
• Lundberg, L.G., Lerner, R., Sundelin, P., Rogers, R., Follcman, J. and Palmblad, J. (2000) "Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity", Am. J. Pathol., 157, 15–19.
   Web of Science ®Google Scholar
• Mesa, R.A., Hanson, CA., Li, C.Y., Yoon, S.Y., Rajkumar, S.V., Schroeder, G. and Tefferi, A. (2002) "Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia", Blood, 99, 4131–4137.
   Google Scholar
• Thiele, J., Kvasnicka, H.M., Fischer, R. and Diehl, V. (1997) "Clinicopathological impact of the interaction between megakar-yocytes and myeloid stroma in chronic myeloproliferative dis-orders: a concise update", Leuk Lymphoma, 24, 463–481.
   PubMed Web of Science ®Google Scholar
• Dupriez, B., Morel, P., Demory, J.L., Lai, J.L., Simon, M., Plantier, I. and Bauters, F. (1996) "Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system", Blood, 88, 1013 — 1018.
   Google Scholar
• Barosi, G., Berzuini, C., Liberato, L.N., Costa, A., Polino, G. and Ascari, E. (1988) "A prognostic classification of myelofibrosis with myeloid metaplasia [see comments]", Br. J. Haematol., 70, 397 — 401.
   Web of Science ®Google Scholar
• Rupoli, S., Da Lio, L., Sisti, S., Campanati, G., Salvi, A., Brianzoni, M.F., et al. (1994) "Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival", Ann. Hematol., 68, 205 — 212.
   Web of Science ®Google Scholar
• Cervantes, F., Pereira, A., Esteve, J., Rafel, M., Cobo, F., Rozman, C. and Montserrat, E. (1997) "Identification of 'short-lived" and long-lived" patients at presentation of idiopathic myelofibrosis", Br. J. Haematol., 97, 635–640.
   Web of Science ®Google Scholar
• Pugh, C.W. and Ratcliffe, P.J. (2003) "Regulation of angiogenesis by hypoxia: role of the HIF system", Nat. Med., 9, 677 — 684.
   Web of Science ®Google Scholar
• Body, LI. (1999) "The syndrome of anorexia-cachexia", Curr. Opin. OncoL, 11, 255–260.
   PubMedGoogle Scholar
• Chang, J.W., Yeh, KN., Shen, Y.C., Hsieh, Li., Chuang, C.K., Liao, S.K., et al. (2003) "Production of multiple cytolcines and induction of cachexia in athymic nude mice by a new anaplastic thyroid carcinoma cell line", J. EndocrinoL, 179, 387 — 394.
   PubMed Web of Science ®Google Scholar
• Zugmaier, G., Paik, S., Wilding, G., Knabbe, C., Bano, M., Lupu, R., et al. (1991) "Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice", Cancer Res., 51, 3590 — 3594.
   Web of Science ®Google Scholar
• Mesa, R.A., Elliott, M.A. and Tefferi, A. (2000) "Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid meta-plasia", Blood Rev., 14, 121–129.
   PubMed Web of Science ®Google Scholar
• Ruegg, C., Yilmaz, A., Bieler, G., Bamat, J., Chaubert, P. and Lejeune, F.J. (1998) "Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma", Nat. Med., 4, 408 — 414.
   Web of Science ®Google Scholar
• Berse, B., Hunt, J.A., Diegel, R.J., Morganelli, P., Yeo, K., Brown, F. and Fava, R.A. (1999) "Hypoxia augments cytolcine (trans-forming growth factor-beta (TGF-beta) and IL-1)-induced vascu-lar endothelial growth factor secretion by human synovial fibroblasts", Clin. Exp. Immunol., 115, 176— 182.
   PubMed Web of Science ®Google Scholar
• Donovan, D., Harmey, J.H., Toomey, D., Osborne, D.H., Red-mond, H.P. and Bouchier-Hayes, DJ. (1997) "TGF beta-1 regulation of VEGF production by breast cancer cells", Ann. Surg. Oncol., 4, 621–627.
   PubMed Web of Science ®Google Scholar
• Harmey, J.H., Dimitriadis, E., Kay, E., Redmond, H.P. and Bouchier-Hayes, D. (1998) "Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1", Ann. Surg. Oncol., 5, 271 — 278.
   Web of Science ®Google Scholar
• Musolino, C., Calabro, L., Bellomo, G., Martello, F., Loteta, B., Pezzano, C., et al. (2002) "Soluble angiogenic factors: implications for chronic myeloproliferative disorders", Am. J. Hematol., 69, 159— 163.
   PubMed Web of Science ®Google Scholar
• Murphy, P., Ahmed, N. and Hassan, H.T. (2002) "Increased serum levels of vascular endothelial growth factor correlate with splenomegaly in polycythemia vera", Leuk. Res., 26, 1007–1010.
   Google Scholar
• Panteli, K., Zagorianakou, N., Bai, M., Katsaralci, A., Agnantis, N.J. and Bourantas, K. (2004) "Angiogenesis in chronic myelo-proliferative diseases detected by CD34 expression", Eur. J. Haematol., 72, 410–415.
   PubMed Web of Science ®Google Scholar
• Di Raimondo, F., Azzaro, M.P., Palumbo, GA., Bagnato, S., Stagno, F., Giustolisi, G.M., et al. (2001) "Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis", Leukemia, 15, 976–980.
   Google Scholar
• Molica, S., Santoro, R., Iuliano, F., Di Raimondo, F., Fichera, E. and Giustolisi, R. (2001) "Serum levels of vascular endothelial growth factor in chronic leukemias. A comparative study with emphasis on myeloproliferative disorders", Haematologica, 86, 771.
   PubMed Web of Science ®Google Scholar
• Di Raimondo, F., Palumbo, G.A., Molica, S. and Giustolisi, R. (2001) "Angiogenesis in chronic myeloproliferative diseases", Acta Haematol., 106, 177 — 183.
   Web of Science ®Google Scholar
• Lee, J.K., Hong, Y.J., Han, CJ., Hwang, D.Y. and Hong, S.I. (2000) "Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen?" Int. J. Oncol., 17, 149 — 152.
   PubMed Web of Science ®Google Scholar
• Wynendaele, W., Derua, R., Hoylaerts, M.F., Pawinslci, A., Waelkens, E., de Bruijn, E.A., et al. (1999) "Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?", Ann. °flea, 10, 965–971.
   Google Scholar
• Gunsilius, E. and Gastl, G. (1999) "Platelets and VEGF blood levels in cancer patients", Br. J. Cancer, 81, 185–186.
   Web of Science ®Google Scholar
• Martyre, MC., Romquin, N., Le Bousse-Kerdiles, MC., Chevil-lard, S., Benyahia, B., Dupriez, B., et al. (1994) "Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis", Br. J. Haematol., 88, 9 — 16.
   Web of Science ®Google Scholar
• Le Bousse-Kerdiles, MC., Martyre, M.C. and French Irno, I.M. (2001) "Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis", Pathologie et Biologie, 49, 153–157.
   Google Scholar
• Chou, J.M., Li, C.Y. and Tefferi, A. (2003) "Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia", Leuk. Res., 27, 499 — 504.
   Google Scholar
• Pruneri, G., Bertolini, F., Soligo, D., Carboni, N., Cortelezzi, A., Ferrucci, P.F., et al. (1999) "Angiogenesis in myelodysplastic syndromes [In Process Citation]", Br. J. Cancer, 81, 1398–1401.
   Web of Science ®Google Scholar
• Mohle, R., Green, D., Moore, MA., Nachman, R.L. and Rafii, S. (1993) "Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets", Proc. Natl. Acad. Sci. USA, 94, 663–668.
   Web of Science ®Google Scholar
• Bellamy, W.T., Richter, L., Frutiger, Y. and Grogan, T.M. (1999) "Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies", Cancer Res., 59, 728–733.
   PubMed Web of Science ®Google Scholar
• Kimura, A., Katoh, 0., Hyodo, H. and Kuramoto, A. (1989) "Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts", Br. J. Haematol., 72, 486–491.
   PubMed Web of Science ®Google Scholar
• Rameshwar, P., Chang, VT., Thacker, U.F. and Gascon, P. "Systemic transforming growth factor-beta in patients with bone marrow fibrosis —pathophysiological implications", Am. J. Hema-tol., 59, 133–142.
   Google Scholar
• Wrobel, T., Mazur, G., Surowiak, P., Wolowiec, D., Jelen, M. and Kuliczkowsky, K. "Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD)", Pathol. Oncol. Res., 9, 170— 173.
   Google Scholar
• Mesa, R., Kay, N., Li, C.Y., Bone, N., Gray, L. and Tefferi, A. (2002) "Urinary markers of angiogenesis and their correlation with intramedullary manifestations of angiogenesis in myelofibrosis with myeloid metaplasia", Blood, 100, 347b —347b.
   Google Scholar
• Vacca, A., Ria, R., Ribatti, D., Semeraro, F., Djonov, V., Di Raimondo, F. and Dammacco, F. (2003) "A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma", Haematologica, 88, 176 — 185.
   Google Scholar
• Kvasnicka, H.M., Thiele, J., Staib, P., Schmitt-Graeff, A., Griesshammer, M., Klose, J., Engels, K. and Kriener, S., (2004) "Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (5T1571) therapy", Blood, 103, 3549 — 3551.
   Web of Science ®Google Scholar
• Kvasnicka, H.M., Thiele, J., Staib, P., Engels, K., Kriener, S. and Schmitt-Graeff, A. (2004) "Therapy-related changes of angiogen-esis in Philadelphia chromosome positive chronic myelogenous leukemia", Pathologe, 25, 127— 134.
   Google Scholar
• Piccaluga, P.P., Visani, G., Pileri, S.A., Ascani, S., Grafone, T., Isidori, A., et al. (2002) "Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study", Leukemia, 16, 1609–1614.
   Web of Science ®Google Scholar
• Strupp, C., Germing, U., Scherer, A., Kundgen, A., Modder, U., Gattermann, N. and Haas, R. (2004) "Thalidomide for the treatment of idiopathic myelofibrosis", Eur. J. Haematol., 72, 52–57.
   PubMed Web of Science ®Google Scholar
• Elliott, MA., Mesa, R.A., Li, C.Y., Hook, C.C., Ansell, S.M., Levitt, R.M., et al. (2002) "Thalidomide treatment in myelofibrosis with myeloid metaplasia", Br. J. Haematol., 117, 288–296.
   Web of Science ®Google Scholar
• Mesa, R.A., Steensma, D.P., Pardanani, A., Li, C.Y., Elliott, M., Kaufmann, S.H., etal. (2003) "A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofi-brosis with myeloid metaplasia", Blood, 101, 2534 — 2541.
   Google Scholar
• Barosi, G., Vittorio, R., Margherita, M., Luca, V.G., Alessandro, P., Vittorio, N., et al. (2004) "Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia", Br. J. Haematol., 124, 618–625.
   Web of Science ®Google Scholar
• Shimizu, K. and Oku, N. (2004) "Cancer anti-angiogenic therapy", Biol. Pharm. Bull., 27, 599–605.
   Google Scholar
• Kerbel, R.S., Yu, J., Tran, J., Man, S., Viloria-Petit, A., Klement, G., et al. (2001) "Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches", Cancer Metastasis Rev., 20, 79–86.
   PubMed Web of Science ®Google Scholar
• Barosi, G., Grossi, A., Comotti, B., Musto, P., Gamba, G. and Marchetti, M. (2001) "Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia", Br. J. Haematol., 114, 78–83.
   Web of Science ®Google Scholar
• Marchetti, M., Barosi, G., Balestri, F., Viarengo, G., Gentili, S., Barulli, S., et al. (2004) "Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial", J. Clin. °flea, 22, 424–431.
   Google Scholar
• Iyer, C.G., Languillon, J., Ramanujam, K., Tarabini-Castellani, G., De las Aguas, J.T., Bechelli, L.M., et al. (1971) "WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients", Bull. World Health Organ., 45, 719–732.
   PubMed Web of Science ®Google Scholar
• Parker, P.M., Chao, N., Nademanee, A., O'Donnell, M.R., Schmidt, G.M., Snyder, D.S., et al. (1995) "Thalidomide as salvage therapy for chronic graft-versus-host disease", Blood, 86, 3604— 3609.
   Google Scholar
• Jacobson, J.M., Greenspan, J.S., Spritzler, J., Ketter, N., Fahey, J.L., Jackson, J.B., et al. (1997) "Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group", N. EngL J. Med., 336, 1487 — 1493.
   Web of Science ®Google Scholar
• Fishman, S.J., Feins, N.R., D'Amoto, R.J. and Follcman, J. (2000) "Thalidomide for Crohn's disease", Gastroenterology, 119, 596.
   Google Scholar
• Rousseau, L., Beylot-Barry, M., Doutre, M.S. and Beylot, C. (1998) "Cutaneous sarcoidosis successfully treated with low doses of thalidomide", Arch. Dermatol., 134, 1045–1046.
   Web of Science ®Google Scholar
• D'Amato, R.J., Loughnan, M.S., Flynn, E. and Follcman, J. (1994) "Thalidomide is an inhibitor of angiogenesis", Proc. Natl. Acad. Sci. USA, 91, 4082–4085.
   PubMed Web of Science ®Google Scholar
• Kenyon, B.M., Browne, F. and D'Amato, R.J. (1997) "Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization", Exp. Eye Res., 64, 971 —978.
   Web of Science ®Google Scholar
• Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., et al. (1999) "Antitumor activity of thalidomide in refractory multiple myeloma", N. EngL J. Med., 341, 1565— 1571.
   Web of Science ®Google Scholar
• Moreira, AL., Sampaio, E.P., Zmuidzinas, A., Frindt, P., Smith, K.A. and Kaplan, G. (1993) "Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation", J. Exp. Med., 177, 1675 — 1680.
   Web of Science ®Google Scholar
• Turk, BE., Jiang, H. and Liu, J.0. (1996) "Binding of thalidomide to alpha 1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production", Proc. Nat! Acad. Sci. USA, 93, 7552–7556.
   Web of Science ®Google Scholar
• Sampaio, E.P., Sarno, E.N., Galilly, R., Cohn, Z.A. and Kaplan, G. (1991) "Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes", J. Exp. Med., 173, 699–703.
   PubMed Web of Science ®Google Scholar
• Geitz, H., Handt, S. and Zwingenberger, K. (1996) "Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade", Immunopharmacology, 31, 213–221.
   Google Scholar
• Haslett, PA., Corral, L.G., Albert, M. and Kaplan, G. (1998) "Thalidomide costimulates primary human T lymphocytes, pre-ferentially inducing proliferation, cytolcine production, and cyto-toxic responses in the CD8 + subset", J. Exp. Med., 187, 1885 — 1892.
   PubMed Web of Science ®Google Scholar
• Haslett, P.A., Hanekom, W.A., Muller, G. and Kaplan, G. (2003) "Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8 + T cells in vitro", J. Infect. Dis., 187, 946–955.
   Web of Science ®Google Scholar
• Davies, FE., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.T., et al. (2001) "Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma", Blood, 98, 210–216.
   Google Scholar
• Canepa, L., Ballerini, F., Varaldo, R., Quintino, S., Reni, L., Clavio, M., et al. (2001) "Thalidomide in agnogenic and secondary myelofibrosis", Br. J. Haematol., 115, 313–315.
   Web of Science ®Google Scholar
• Pozzato, G., Zorat, F., Nascimben, F., Comar, C., Kilcic, F. and Festini, G. (2001) "Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia", Haema-tologica, 86, 772–773.
   Google Scholar
• Merup, M., Kutti, J., Birgergard, G., Mauritzson, N., Bjorkholm, M., Markevarn, B., et al. (2002) "Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metapla-sia", Med. OncoL, 19, 79–86.
   Google Scholar
• Barosi, G., Elliott, M., Canepa, L., Ballerini, F., Piccaluga, P.P., Visani, G., et al. (2002) "Thalidomide in myelofibrosis with myeloid metaplasia: A pooled-analysis of individual patient data from five studies", Blood, 100, 800a–800a.
   Google Scholar
• Mesa, R.A., Elliott, MA., Schroeder, G. and Tefferi, A. (2004) "Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia", Mayo Clinic Proceedings, 79, 883–889.
   Google Scholar
• Ebos, J.M., Tran, J., Master, Z., Dumont, D., Melo, J.V., Buchdunger, E. and Kerbel, R.S. (2002) "Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia", Mol. Cancer Res., 1, 89–95.
   Web of Science ®Google Scholar
• Buchdunger, E., O'Reilly, T. and Wood, J. (2002) "Pharmacology of imatinib (5TI571)", Eur. J. Cancer, 38\(Suppl 5), S28— S36.
   PubMed Web of Science ®Google Scholar
• Kvasnicka, H.M., Thiele, J., Staib, P., Schmitt-Graeff, A., Griesshammer, M., Klose, J., et al. (2004) "Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (5TI571) therapy", Blood, n, 00–00.
   Google Scholar
• Tefferi, A., Mesa, R.A., Gray, L.A., Steensma, D.P., Camoriano, J.K., Elliott, MA., et al. (2002) "Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia", Blood, 99, 3854 — 3856.
   Google Scholar
• De Angelo, D.J., Soiffer, R.J., Galinisky, I., Clark, J.J., Gilliland, D.G., Shanahan, J., et al. (2003) "Imatinib mesylate (Gleevec (R)) for patients with chronic idiopathic myelofibrosis (CIM): A phase II trial", Blood, 102, 146a–146a.
   Google Scholar
• Hasselbalch, H.C., Bjerrum, 0.W., Jensen, BA., Clausen, N.T., Hansen, P.B., Birgens, H., et al. (2003) "Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis", Am. J. HematoL, 74, 238–242.
   PubMed Web of Science ®Google Scholar
• Ho, A.Y.L., Lim, S., Fishlock, K., Yang, T.H., Westwood, N., Devereux, S., et al. (2002) "Imatinib mesylate in myelofibrosis: Preliminary results show early sustained improvements in platelet counts and splenomegaly", Blood, 100, 799a–799a.
   Google Scholar
• Gisslinger, H., Gisslinger, B., Kees, M., Maurer, U., Schoder, R., Grumbeck, E., et al. (2002) "Imatinib mesylate in chronic idiopathic myelofibrosis, a phase II trial", Blood, 100, 800a–801a.
   Google Scholar
• Cortes, J., Ault, P., Koller, C., Thomas, D., Ferrajoli, A., Wierda, W., et al. (2003) "Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome", Blood, 101, 4714–4716.
   Google Scholar
• Giles, F.J., Stopeck, AT., Silverman, L.R., Lancet, J.E., Cooper, MA., Hannah, AL., et al. (2003) "5U5416, a small molecule tyrosine lcinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes", Blood, 102, 795–801.
   PubMed Web of Science ®Google Scholar
• Smolich, B.D., Yuen, HA., West, K.A., Giles, F.J., Albitar, M. and Cherrington, J.M. (2001) "The antiangiogenic protein kinase inhibitors 5U5416 and 5U6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts", Blood, 97, 1413–1421.
   PubMed Web of Science ®Google Scholar
• Giles, F.J., Cooper, MA., Silverman, L., Karp, J.E., Lancet, J.E., Zangari, M., et al. (2003) "Phase II study of 5U5416— a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor —in patients with refractory myeloproliferative diseases", Cancer, 97, 1920— 1928.
   Web of Science ®Google Scholar
• Roboz, G.J., List, A.F., Giles, F., Rae, P.E., Dugan, M., Greenberg, J., et al. (2002) "Phase I trial of PTK787/ZK 222584, an inhibitor of vascular endothelial growth factor receptor tyrosine lcinases, in acute myeloid leukemia and myelodysplastic syn-drome", Blood, 100, 337a.
   Google Scholar
• Feldkamp, MM., Lau, N. and Guha, A. (1999) "Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects", Oncogene, 18, 7514–7526.
   Google Scholar
• Reuter, C.W., Morgan, MA. and Bergmann, L. (2000) "Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?", Blood, 96, 1655–1669.
   Google Scholar
• Mesa, R.A., Tefferi, A., Gray, L.A., Reeder, T., Schroeder, G. and Kaufmann, S.H. (2003) "In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia", Leukemia, 17, 849–855.
   PubMed Web of Science ®Google Scholar
• Cortes, J., Albitar, M., Thomas, D., Giles, F., Kurzrock, R., Thibault, A., et al. (2003) "Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies", Blood, 101, 1692–1697.
   Web of Science ®Google Scholar
• Mesa, R.A., Camoriano, J.K., Geyer, S.M., Kaufmann, S.H., Erlichman, C., Juckett, M. and Tefferi, A. (2003) "A phase 2 consortium (P2C) trial of r115777 (Zarnestra) in myelofibrosis with myeloid metaplasia: Interim analysis of 18 patients", Blood, 102, 922a.
   Web of Science ®Google Scholar